Last patient last visit (LPLV) milestone in AFFIRM-1 Phase 3 trial of BNC-210 in social anxiety disorder (SAD) achieved; topline readout anticipated in early Q4 2025
Cash runway extended through fiscal Q2 2027
BURLINGTON, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) — Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today reported its financial results for its fiscal year ended June 30, 2025, and provided recent business updates.
“It is an exciting time for Neuphoria as we rapidly approach topline data from our AFFIRM-1 Phase 3 study of BNC-210 in social anxiety disorder, which is anticipated early in the fourth quarter of this year,” said Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Neuphoria. “BNC-210 is supported by a robust body of clinical data, demonstrating clinically meaningful effects across multiple stress and anxiety indications. These data, along with its differentiated safety profile, give us confidence in BNC-210 as a potentially transformative treatment for patients struggling with SAD.”
Clinical Program Highlights
- The LPLV milestone has been achieved in the AFFIRM-1 Phase 3 trial evaluating BNC-210 as a first-in-class, acute, “as needed” treatment for SAD. Topline data are anticipated in early fourth quarter 2025.
- Start-up activities continue for the SYMPHONY Phase 2b/3 trial in PTSD. Neuphoria plans to initiate the clinical study in the first half of 2026.
- MK-1167, one of two positive allosteric modulator (PAM) candidates being advanced in a strategic partnership with Merck & Co, Inc., is currently being evaluated in a Merck-led Phase 2 trial in Alzheimer’s disease.
June 30
th
Fiscal Year-End 2025 Financial Results and Key Highlights
Cash Position: Cash and cash equivalents were $14.2 million as of June 30, 2025. The Company expects its current cash position to be sufficient to fund operations through the second fiscal quarter of 2027.
R&D Expenses: Research and development expenses were $9.0 million for the year ended June 30, 2025, compared to $9.4 million for the year ended June 30, 2024. The decrease of $0.4 million was primarily due to the timing of clinical and consulting related spend.
G&A Expenses: General and administrative expenses were $7.8 million for the year ended June 30, 2025, compared to $8.5 million for the year ended June 30, 2024. The decrease of $0.7 million was primarily due to decreases in headcount and insurance costs.
Net Loss: Net loss was $0.4 million, or $0.23 per basic and diluted share, for the year ended June 30, 2025, compared to a net loss of $15.5 million, or $18.62 per basic and diluted share, for the year ended June 30, 2024.
About BNC-210
BNC-210 is an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor under development for the treatment of SAD and post-traumatic stress disorder (PTSD). BNC-210 has been given FDA Fast Track designation for acute treatment of SAD and other anxiety related disorders, and for treatment of PTSD and other trauma and stressor related disorders. BNC-210 has demonstrated rapid-onset, broad and meaningful anti-anxiety effects in completed clinical trials in SAD, generalized anxiety disorder (GAD) and panic attacks without evidence of sedation, impairments in cognition or addiction potential.
About Neuphoria Therapeutics Inc.
Neuphoria (Nasdaq: NEUP) is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. Neuphoria is advancing its lead drug candidate, BNC-210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute, “as needed” treatment of social anxiety disorder (SAD) and for chronic treatment of post-traumatic stress disorder (PTSD). BNC-210 is a first-of-its-kind, well-tolerated, broad spectrum anti-anxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. In addition, Neuphoria has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions. Neuphoria’s pipeline also includes the α7 nicotinic acetylcholine receptor next generation and the Kv3.1/3.2 preclinical programs, both in the lead optimization development stage.
Forward-Looking Statements
Neuphoria cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as “may,” “could,” “will,” “would,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “intend,” “predict,” “seek,” “contemplate,” “potential,” “continue” or “project” or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. The forward-looking statements are based on our current beliefs, plans, burn rate and expectations. Certain forward-looking statements, including (without limitation) about (1) Neuphoria’s ability to develop and expand its business, successfully complete development of its current product candidates, the timing of commencement and/or completion, as well as any successful or other outcome of various clinical trials, and receipt of data and current and future collaborations for the development and commercialization of its product candidates, (2) the market for drugs to treat CNS diseases and pain conditions, and the Company’s ability to realize the commercial potential of its products, as well as its regulatory strategy related to its clinical trials and, if successful, the regulatory pathway to any next stage in development or commercialization, (3) Neuphoria’s financial resources, and capital allocation and corporate development strategy, and (4) assumptions underlying any such statements. The inclusion of forward-looking statements should not be regarded as a representation by Neuphoria that any of its plans will be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. Certain forward-looking statements involve contracts, licenses and arrangements involving third parties and their respective clinical trial and research and development projects that are out of our control, including our agreements with Merck and Carina. They may terminate or delay any or all such projects in their discretion pursuant to the terms of our agreements with them, which could result in the Company not realizing any further milestone payments or further progress on the respective product pathways. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company’s business and other risks described in the Company’s filings with the SEC, including the Company’s Annual Report on Form 10-K, Quarterly Report on Form 10-Q, Current Reports on Form 8-K, each filed with the SEC, and its other reports. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Neuphoria undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks, uncertainties and other factors is included in Neuphoria’s filings with the SEC, copies of which are available from the SEC’s website (www.sec.gov) and on Neuphoria’s website (www.neuphoriatx.com) under the heading “Investor Center.” All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. Neuphoria expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.
FOR FURTHER INFORMATION PLEASE CONTACT:
|
General Spyridon (Spyros) Papapetropoulos [email protected] |
IR & PR Argot Partners [email protected] |
|
Consolidated Balance Sheet (unaudited) |
|||||||
| June 30, | June 30, | ||||||
| 2025 | 2024 | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 14,210,745 | $ | 12,608,109 | |||
| Accounts receivable, non-trade | 11,948 | 126,884 | |||||
| Restricted cash | 77,945 | — | |||||
| Prepaid expenses | 740,193 | 458,765 | |||||
| Total current assets | 15,040,831 | 13,193,758 | |||||
| Property and equipment, net | 2,771 | 1,994 | |||||
| Intangible assets, net | 4,804,791 | 5,467,522 | |||||
| Operating lease right-of-use assets | 102,612 | 216,975 | |||||
| Restricted cash | — | 78,826 | |||||
| Goodwill | 8,638,609 | 8,690,018 | |||||
| Total assets | $ | 28,589,614 | $ | 27,649,093 | |||
| Liabilities and shareholders’ equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 1,154,369 | $ | 2,243,662 | |||
| Accrued expenses and other current liabilities | 2,950,077 | 1,463,421 | |||||
| Operating lease liability | 116,314 | 121,990 | |||||
| Total current liabilities | 4,220,760 | 3,829,073 | |||||
| Operating lease liability, net of current portion | — | 117,628 | |||||
| Contingent consideration | 1,169,675 | 587,762 | |||||
| Deferred tax liability | 495,113 | 963,540 | |||||
| Accompanying warrant liability | 3,701,492 | 4,657,832 | |||||
| Other non-current liabilities | — | 2,886 | |||||
| Total liabilities | 9,587,040 | 10,158,721 | |||||
| Commitments and contingencies | |||||||
| Shareholders’ equity: | |||||||
| Common stock, $0.00001 par value, 1,978,460 and 1,103,954 shares issued and outstanding at June 30, 2025 and 2024, respectively | 19 | 11 | |||||
| Additional paid-in capital, net of subscription receivable | 200,194,324 | 198,481,027 | |||||
| Accumulated other comprehensive loss, net of tax | (2,845,066 | ) | (3,013,595 | ) | |||
| Accumulated deficit | (178,346,703 | ) | (177,977,071 | ) | |||
| Total shareholders’ equity | 19,002,574 | 17,490,372 | |||||
| Total liabilities and shareholders’ equity | $ | 28,589,614 | $ | 27,649,093 | |||
|
Consolidated Statement of Operations (unaudited) |
|||||||
| Year Ended June 30, | |||||||
| 2025 | 2024 | ||||||
| License revenue | $ | 15,649,448 | $ | – | |||
| Operating expenses: | |||||||
| Research and development | 9,005,097 | 9,417,785 | |||||
| General and administrative | 7,773,442 | 8,474,591 | |||||
| Total operating expenses | 16,778,539 | 17,892,376 | |||||
| Loss from operations | (1,129,091 | ) | (17,892,376 | ) | |||
| Other income (loss): | |||||||
| Interest income, net | 166,498 | 220,097 | |||||
| Loss on foreign currency transactions | (414,996 | ) | (209,842 | ) | |||
| Research and development incentive award | 299,905 | 95,215 | |||||
| Gain on fair value adjustments | 239,686 | 2,207,420 | |||||
| Total other income | 291,093 | 2,312,890 | |||||
| Loss before income tax benefit | (837,998 | ) | (15,579,486 | ) | |||
| Income tax benefit | 468,366 | 87,320 | |||||
| Net loss | (369,632 | ) | (15,492,166 | ) | |||
| Other comprehensive income: | |||||||
| Unrealized gain on foreign currency translation | 168,529 | 45,188 | |||||
| Total other comprehensive income | 168,529 | 45,188 | |||||
| Total comprehensive loss | $ | (201,103 | ) | $ | (15,446,978 | ) | |
| Net loss per share – basic and diluted | $ | (0.23 | ) | $ | (18.62 | ) | |
| Weighted-average common shares outstanding – basic and diluted | 1,622,924 | 832,225 | |||||
|
Consolidated Statement of Cash Flows (unaudited) |
|||||||
| Year Ended June 30, | |||||||
| 2025 | 2024 | ||||||
| Cash flows from operating activities: | |||||||
| Net loss | $ | (369,632 | ) | $ | (15,492,166 | ) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||||
| Share-based compensation | 163,772 | 814,808 | |||||
| Depreciation and amortization expense | 662,890 | 662,991 | |||||
| Non-cash rent expense | 114,363 | 113,503 | |||||
| Change in fair value of accompanying warrant liability | (956,340 | ) | (338,983 | ) | |||
| Change in fair value of contingent consideration | 716,654 | (1,868,437 | ) | ||||
| Effect of foreign currency remeasurement | 242,348 | (27,350 | ) | ||||
| Changes in assets and liabilities: | |||||||
| Accounts receivable, non-trade | 114,936 | 299,203 | |||||
| Prepaid expenses | (453,058 | ) | 338,713 | ||||
| Accounts payable | (917,663 | ) | 804,371 | ||||
| Accrued expenses and other current liabilities | 1,486,656 | 277,854 | |||||
| Operating lease liabilities | (123,304 | ) | (114,147 | ) | |||
| Deferred tax liability | (468,427 | ) | (139,173 | ) | |||
| Contingent consideration | (133,080 | ) | – | ||||
| Other non-current liabilities | (2,886 | ) | (11,964 | ) | |||
| Net cash provided by (used in) operating activities | 77,229 | (14,680,777 | ) | ||||
| Cash flows from financing activities: | |||||||
| Proceeds from the sale of equity, net of subscriptions receivable of $0.1 million and issuance costs of $0.1 million | 1,528,276 | – | |||||
| Proceeds from the sale of equity, net of issuance costs of $1.3 million | – | 10,111,979 | |||||
| Proceeds from the sale of accompanying warrant | – | 4,996,815 | |||||
| Net cash provided by financing activities | 1,528,276 | 15,108,794 | |||||
| Effect of exchange rate on changes on cash, cash equivalents, and restricted cash | (3,750 | ) | 76,974 | ||||
| Net increase in cash, cash equivalents, and restricted cash | 1,601,755 | 504,991 | |||||
| Cash, cash equivalents, and restricted cash, beginning of period | 12,686,935 | 12,181,944 | |||||
| Cash, cash equivalents, and restricted cash, end of period | $ | 14,288,690 | $ | 12,686,935 | |||
